

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

FIGURE 1

Human G Protein Coupled Receptor Family
 (Receptors known as of January, 1999)

CLASS	LIGAND	NUMBER	TISSUE	PHYSIOLOGY	THERAPEUTICS
•Class I Rhodopsin like	•Amine				
	·Acetylcholine (muscarninic & nicotinic)	5	Brain, Nerves, Heart	Neurotransmitter	Acuity, Alzheimer's
	·Adrenoceptors				
	·Alpha Adrenoceptors	6	Brain, Kidney, Lung	Gluconeogenesis	Diabetes, Cardiovascular
	·Beta Adrenoceptors	3	Kidney, Heart	Muscle Contraction	Cardiovascular, Respiratory
	·Dopamine	5	Brain, Kidney, GI	Neurotransmitter	Cardiovascular, Parkinson's
	·Histamine	2	Vascular, Heart, Brain	Vascular Permeability	Anti-inflammatory, Ulcers
	·Serotonin (5-HT)	16	Most Tissues	Neurotransmitter	Depression, Insomnia, Analgesic
	·Peptide				
	·Angiotensin	2	Vascular, Liver, Kidney	Vasoconstriction	Cardiovascular, Endocrine
	·Bradykinin	1	Liver, Blood	Vasodilation,	Anti-inflammatory, Asthma
	·C5a anaphylatoxin	1	Blood	Immune System	Anti-inflammatory
	·Fmet-leu-phe	3	Blood	Chemoattractant	Anti-inflammatory
	·Interleukin-8	1	Blood	Chemoattractant	Anti-inflammatory
	·Chemokine	6	Blood	Chemoattractant	Anti-inflammatory
	·Orexin	2	Brain	Fat Metabolism	Obesity
	·Nociceptin	1	Brain	Bronchodilator, Pain	Airway Diseases, Anesthetic
	·CCK (Gastrin)	2	Gastrointestinal	Motility, Fat Absorption	Gastrointestinal, Obesity, Parkinson's
	·Endothelin	2	Heart, Bronchus, Brain	Muscle Contraction	Cardiovascular, Respiratory
	·Melanocortin	5	Kidney, Brain	Metabolic Regulation	Anti-inflammatory, Analgesics
	·Neuropeptide Y	5	Nerves, Intestine, Blood	Neurotransmitter	Behavior, Memory, Cardiovascular
	·Neurotensin	1	Brain,	CNS	Cardiovascular, Analgesic
	·Opioid	3	Brain,	CNS	Depression, Analgesic
	·Somatostatin	5	Gastrointestinal	Neurotransmitter	Oncology, Alzheimer's

·Tachykinin (Substance P, NK _A)	3	Brain Nerves	Neurohormone
·Thrombin	3	Platelets, Blood Vessels	Coagulation
·Vasopressin-like	4	Arteries, Heart, Bladder	Water Balance
·Galanin	1	Brain, Pancreas	Neurotransmitter
·Hormone protein			
·Follicle stimulating hormone	1	Ovary, Testis	Endocrine
·Lutropin-choriogonadotropin	1	Ovary, Testis	Endocrine
·Thyrotropin	1	Thyroid	Endocrine
·(Rhod)opsin			
·Opsin	5	Eye	Photoreception
·Olfactory	4(~1000)	Nose	Smell
·Prostanoid			
·Prostaglandin	5	Arterial, Gastrointestinal Vessels, Heart, Lung	Vasodilation, Pain Inflammation
·Lysophosphatidic Acid	2	Most Cells	Cell proliferation
·Sphingosine-1-phosphate	2	White Blood Cells, Bronchus	Inflammation
·Leukotriene	1	Arterial, Gastrointestinal	Platelet Regulation
·Prostacyclin	1	Arterial, Bronchus	Vasoconstriction
·Thromboxane	1		
·Nucleotide-like			
·Adenosine	4	Vascular, Bronchus	Multiple Effects
·Purinoceptors	4	Vascular, Platelets	Relaxes Muscle
·Cannabis	2	Brain	Sensory Perception
·Platelet activating factor	1	Most Peripheral Tissues	Inflammation
·Gonadotropin-releasing hormone like			
·Gonadotropin-releasing hormone	1	Reproductive Organs, Pituitary Reproduction	Prostate Cancer, Endometriosis
·Thyrotropin-releasing hormone	1	Pituitary, Brain	Metabolic Regulation
·Growth hormone- inhibiting factor	1	Gastrointestinal	Oncology, Alzheimer's
·Melatonin	1	Brain, Eye, Pituitary	Regulation of Circadian Cycle

Figure 1, pg. 2 of 3

•Class II Secretin like	•Secretin	1	Gastrointestinal, Heart Bone, Brain	Digestion Calcium Resortion	Obesity, Gastrointestinal Osteoporosis
	•Calcitonin	1			
	•Corticotropin releasing factor/urocortin	1	Adrenal, Vascular, Brain Adrenals, Fat Cells	Neuroendocrine Sugar/Fat Metabolism	Stress, Mood, Obesity Diabetes, Obesity
	•Gastric inhibitory peptide (GIP)	1	Liver, Fat Cells, Heart	Glucconeogenesis	Cardiovascular
	•Glucagon	1	Pancreas, Stomach, Lung	Brain	Cardiovascular, Diabetes, Obesity
	•Glucagon-like Peptide 1 (GLP-1)	1	1	Calcium Regulation	Neuroendocrine Growth Regulation
	•Growth hormone-releasing hormone	1	Bone, Kidney	Metabolism	Osteoporosis
	•Parathyroid hormone	1	Brain, Pancreas, Adrenals		Metabolic Regulation
	•PACAP	1			
	•Vasoactive intestinal polypeptide (VIP)	1	Gastrointestinal	Motility	Gastrointestinal
•Class III	•Metabotropic Glutamate	7	Brain		Hearing, Vision
	•GABA _B	1	Brain		Mood Disorders
	•Extracellular Calcium Sensing	1	Parathyroid, Kidney, GI Tract	Calcium Regulation	Cataracts, GI Tumors

Figure 1, pg. 3 of 3

Figure 2

G protein-coupled receptors:

(Division into Class A
Or Class B)

1. **A1 adenosine receptor** [Homo sapiens]. ACCESSION AAB25533
npiwyaf riqkfrvtfl kiwndhfrcq pappidedlp eerpdd
Class A
2. **adrenergic, alpha -1B-, receptor** [Homo sapiens]. ACCESSION NP_000670
npiypcsskefkrafvrlgecqcrgrgrrrrrrrrlggcaytyrpwtrgsslersqsrkdsddsgscldgsqrtpsaspplgylrgap
ppvelcafewkapgallslpapeppgrrgrhdsgplftklltepespgtdggasnggceaaadvangqpgfksnmplapgqf
Class A
3. **adrenergic receptor alpha-2A** [Homo sapiens]. ACCESSION AAG00447
npyiytfnhdfrrafkkilcrgdrkriv
Class A
4. **alpha-2B-adrenergic receptor** - human. ACCESSION A37223
npyiytfnqdfrfafrrilcrpwqtaw
Class A
5. **alpha-2C-adrenergic receptor** - human. ACCESSION A31237
npyiytvfnqdfbpsfkhilfrrrrgfrq
Class A
6. **beta-1-adrenergic receptor** [Homo sapiens]. ACCESSION NP_000675
npiiycrspdfrkafqglccarraarrhathgdprasgclarpgpppspgaaasdffffvvvatpparlep wagcnggaaads
d ssldpcrpgfaseskv
Class A
7. **beta-2 adrenergic receptor.** ACCESSION P07550
npliycrspdfriafqellclrsslkayngyssngntgeqsgyhveqekenkllcedlpgtedfvghqgtvpsdnidsqgrncstd
sll
Class A
8. **dopamine receptor D1** [Homo sapiens]. ACCESSION NP_000785
npiiyafnadfrkafstllgcylcpatnnaietvsinnngaamfsshheprgsiskecnlvyliphavgssedlkkeeagiapplekl
palsvildytdvslekiqpitqngqhpt
Class A
9. **D(2) dopamine receptor.** ACCESSION P14416
npiiyttfniefrkaflkilhc
Class A

10. **d3 dopamine receptor - human.** ACCESSION G01977
npviytfniefrkafklkilsc
Class A
11. **dopamine receptor D4 - human.** ACCESSION DYHUD4
npviytvfnaefrnvfkalacc
Class A
12. **dopamine receptor D5 - human.** ACCESSION DYHUD5
npviyafnqkvfaqlgcshfcsvtpetvnisnelisynqdivfhkeiaayihmmpnavtgnrevdndeeegpfdrmfqi
yqtspdgdpvaesvweldcegeisldkitftpngfh
Class A
13. **muscarinic acetylcholine receptor M1 [Homo sapiens].** ACCESSION NP_000729
nmpcyalcnkafrdtfrlllcwrdkrrwrkipkrpgsvhrtprqc
Class A
14. **muscarinic acetylcholine receptor M2 [Homo sapiens].** ACCESSION NP_000730
npacyalcnatfkktfkhlmcchyknigatr
Class A
15. **muscarinic acetylcholine receptor M3 [Homo sapiens].**
npvcyalcnktfrtfkmlllcqdckkkrrkqqyqqrqsvifhkrapcqal
Class A
16. **muscarinic acetylcholine receptor M4 [Homo sapiens].** ACCESSION NP_000732
npacyalcnatfkktfrhlllcqyrnigtar
Class A
17. **m5 muscarinic receptor.** locus HUMACHRM ACCESSION AAA51569
npicyalcnrtfrkfmlllcrwkkkkveeklywqgnsklp
Class A
18. **5-hydroxytryptamine (serotonin) receptor 1A [Homo sapiens].** ACCESSION BAA90449
npviyayfnkdfqnafkkiikckf
Class A
19. **5-hydroxytryptamine (serotonin) receptor 1B [Homo sapiens].** ACCESSION BAA94455
npiiytmnsnedfkqafhklirkfcts
Class A
20. **5-hydroxytryptamine (serotonin) receptor 1E [Homo sapiens].** ACCESSION BAA94458
npllytsfnedfkafkklicre
Class A
21. **OLFACTORY RECEPTOR 6A1.** ACCESSION O95222

Figure 2
page 3

npiiyclrnqevkralccilhlyqhqdppkgsrnv

Class A

22. **OLFACTORY RECEPTOR 2C1.** ACCESSION O95371

npliytlrnmevkgalrrllgkgrevg

Class A

23. **angiotensin receptor 1 [Homo sapiens].** ACCESSION NP_033611

nplfygflgkkfkryflqlkyippkakshsnlsfkmstfsyrvpsdnvssstkkpapcfeve

Class B

24. **angiotensin receptor 2 [Homo sapiens].** ACCESSION NP_000677

npflycfvgnrqqkrlsvfrvpitwlqgkresmscrkssslremetfvs

Class B

25. **interleukin 8 receptor beta (CXCR2) [Homo sapiens].** ACCESSION NM_001557

NPLIYAFIGQKFRHGLLKILAIHGLISKDSLPKDSRPSFVGSSSGHTSTTL

Class B

26. **cx3c chemokine receptor 1 (cx3cr1) (fractalkine receptor)**

ACCESSION P49238

npliyafagekfrrylyhlygkclavlcgrsvhvdfsssesqrsrhgsvlssnftyhtsdgdalll

Class B

27. **neurotensin receptor - human.** ACCESSION S29506

n pilynlvsanfrhiflatlaclcpvwrrrrrpafsrkadsvssnhflssnatretly

Class B

28. **SUBSTANCE-P RECEPTOR (SPR) (NK-1 RECEPTOR) (NK-1R).** ACCESSION P25103

npiiyccindrfrlgfkhafrccpfisagdyeglemkstrylqtqsvykvsltvtvgaheeepepdgpkatpssldtsncssrsd

sktmtesfsfssnvls

Class B

29. **vasopressin receptor type 2 [Homo sapiens].** ACCESSION AAD16444

npwiyasfsssvselrsllccargrtppslgpqdescattassslakdtss

Class B

30. **thyrotropin-releasing hormone receptor - human.** ACCESSION JN0708

npviynlmssqkfraafrklcncckqkptekpanysvalnsvikesdhfsteldditvtdtylsafkvsfddtclasevsfsqs

Class B

31. **oxytocin receptor - human.** ACCESSION A55493

npwiymftghlfhelvqrflccsasylkgrrlgetsaskksnsssfvlsrsshssqrscsqpsta

Class B

Figure 2
page 4

32. **neuromedin U receptor 1 [Homo sapiens].** ACCESSION AAG24793
npylyslmssrfretfqealclgacchrlprhsshlsrmittgstlcvgsglgswvhplagndgpeaqqetdps
Class B
33. **gastrin receptor.** ACCESSION AAC37528
nplvycfmhrrfrfqacletcarccprpprarpaldedpptsiaslsrlsyttistlpgp
Class B
34. **galanin receptor 3 [Homo sapiens].** ACCESSION 10879541
nplvyalasrhfrarfrrlwpcgrrrhrarralrrvrpassgppgcpgdarpsgrllagggqgpepregpvhggeaargpe
Class A
35. **edg-1 - human.** ACCESSION A35300
npiiytltnkemrrafirimsccckcpsgdsagkfkrpiagmefsrsksdnsshpqkdegdnpetimssgnvnsss
Class A
36. **central cannabinoid receptor [Homo sapiens].** ACCESSION NP_057167
npiiyalrskdlrhafsmfpsegtaqpldnsmgdsdclhkhannaavhraescikstvkiakvtmsvstdtsaeal
Class A
37. **delta opioid receptor - human.** ACCESSION I38532
npylyafldenkrcfrqlcrkpcgrpdpssfsrpreatarervtactpsdgpagggra
Class A
38. **proteinase activated receptor 2 (PAR-2) human.** ACCESSION P55085
dpfvyyfvshdfrdhaknallcrsvrtvkqmqvshtskhsrksssyssssttvktsy
Class B
39. **vasopressive intestinal peptide receptor (VIPR) rat.** ACCESSION NM_012685
NGEVQAEELRRKWRRWHLQGVLGWSSKSQHPWGGSNGATCSTQVSMLTRVSPSARR
SSSFQAEVSLV
Class B

	A	B	C
1	GPCR Agonist	Generic Name	Brand Name
2	5-HT		
3	5-HT-1B/1D	Zolmitriptan	Zomig
4		Rizatriptan	Maxalt
5		Eletriptan	Relpax
6		Trazodone	Desyrel
7	5-HT-1D	Sumatriptan	Imitrex (P)
8		Naratriptan	Amerge
9		Almotriptan	Axert
10	5-HT-1B/1A	Frovatriptan	Frova
11			
12	5-HT-1A	Buspirone	BuSpar
13	5-HT-1A	Buspirone	Generic
14	5-HT-1A	Ziprasidone	Geodon
15			
16	5-HT-4	Tegaserod	Zelnorm
17	5-HT-4	Mosapride	Gasmotin
18	5-HT-4	Cisapride	Propulsid
19			
20	5-HT-2A/2C	Clozapine	Clozaril
21			
22	5-HT-2 / Dopa D1	Femoldopam	Corlopam
23			
24	5-HT/ Opioid u	Tramadol	Ultram
25	5-HT/ Opioid u	Tramadol	Ultracet
26	5-HT/ Opioid u	Tramadol	Generic
27			
28	Opioid		
29	Opioid	Codeine	Generic
30		Hydrocodone	Generic
31		Hydromorphone	Dilaudid
32		Levorphanol	Levo-Dromoran
33		Morphine	MS Contin
34		Morphine	Generic
35		Oxycodone	OxyContin
36		Oxycodone/APAP	Generic
37		Oxymorphone	Numorphan
38		Alfentanil	Alfenta
39		Fentanyl	Duragesic
40		Fentanyl	Sublimaze
41		Meperidine	Demerol
42		Sufentanil	Sufenta
43		Levomethadyl	Orlaam
44		Methadone	Dolophine
45		Propoxyphene	Darvon
46		Buprenorphine	Transtec
47		Remifentanil	Ultiva
48			
49	5-HT/ Opioid u	Tramadol	Ultram
50	5-HT/ Opioid u	Tramadol	Ultracet
51	5-HT/ Opioid u	Tramadol	Generic
52		Fig 3, page 1 of 3	


APPLICATION FILING DATE: OCTOBER 24, 2003
 TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
 TRANSMEMBRANE AGONISTS
 INVENTOR(S): CARSON LOOMIS, ET AL.
 APPLICATION SERIAL NO.: UNASSIGNED


	A	B	C
1	GPCR Agonist	Generic Name	Brand Name
53	ADO		
54	ADO (mixed)	Adenosine	Adenocard
55		Adenosine	Adenoscan
56			
57	Adrenoceptor		
58	Adrenoceptor	Methylphenidate	Generic
59	Beta (mixed)	Isoproterenol	Isuprel
60		Ephedrine	Generic
61		Mephentermine	Wyamine
62	Beta-1	Norepinephrine	Levophed
63			
64	Beta-2	Salmeterol	Serevent
65		Salmeterol/ fluticasone	Advair
66		Albuterol, Aerosol	Generic
67		Albuterol, Sulfate	Generic
68		Albuterol	Proventil
69		Bitolterol	Tornalate
70		Isoetharine	Isoetharine
71		Metaproterenol	Alupent
72		Pirbuterol	Maxair
73		Formoterol	Foradil
74		Formoterol,	Oxis
75		Albuterol	Ventolin HFA
76		Bambuterol	Bambec
77		Salbutamol	Inspiryl Turbuhaler
78		Terbutaline	Brethine
79		Terbutaline	Terbutaline
80	H1 (-) / Beta-2 (+)	Ioratadine/ pseudoephedrine	Claritin-D
81	H1 (-) / Beta-2 (+)	Fexofenadine/ pseudoephedrine	Allegra-D
82		Terbutaline	Brethine
83	Alpha-Beta (mixed)	Metaraminol	Aramine
84		Epinephrine	Generic
85	Alpha (mixed)	Methoxamine	Vasoxyl
86		Phenyephrine	Neo-Synephrine
87	Alpha-1	Modafinil	Provigil
88		Midodrine	ProAmatine
89			
90	Alpha-2	Guanfacine	Tenex
91		Tizanidine SR	Sirdalud CR
92		Moxonidine	Physiotens
93		Dexmedetomidine	Precedex
94		Brimonidine	Alphagen
95		Apraclonidine	Iopidine
96		Fig 3, page 2 of 3	


APPLICATION FILING DATE: OCTOBER 24, 2003
 TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
 TRANSMEMBRANE AGONISTS
 INVENTOR(S): CARSON LOOMIS, ET AL.
 APPLICATION SERIAL NO.: UNASSIGNED


	A	B	C
1	GPCR Agonist	Generic Name	Brand Name
97			
98	Acetylcholine	Bethanechol	Generic
99	Muscarinic AC	Pilocarpine	Salagen
100	Muscarinic AC	Levetiracetam	Kepra
101			
102	Dopamine		
103	Dopamine (mixed)	Dopamine	Intropin
104	D1	Femoldopam	Corlopam
105	D2	Apomorphine	Ixense
106	D2/D3	Ropinirole	Requip
107	D2/D3	Pramipexole	Mirapex
108	D2/D3	Amisulpride	Solian
109	D2 Type	Bromocriptine	Parlodel
110	D1/D2	Pergolide	Permax
111			
112	Prostaglandin F2a (PG F2a)	Latanoprost	Xalatan
113	Prostaglandin F2a (PG F2a)	Unknown	Travatan
114	Prostaglandin E1 (PGE1)	Alprostadil	Befar
115			
116	Gonadotropin-releasing hormone (GnRH)	LHRH agonist	TRELSTAR LA
117	GnRH	Leuprolide	Lupron Depot
118			
119			
120	Calcitonin	Calcitonin	
121		Fig 3, page 3 of 3	


APPLICATION FILING DATE: OCTOBER 24, 2003
 TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
 TRANSMEMBRANE AGONISTS
 INVENTOR(S): CARSON LOOMIS, ET AL.
 APPLICATION SERIAL NO.: UNASSIGNED



























































































APPLICATION FILING DATE: OCTOBER 24, 2003
 TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
 TRANSMEMBRANE AGONISTS
 INVENTOR(S): CARSON LOOMIS, ET AL.
 APPLICATION SERIAL NO.: UNASSIGNED



APPLICATION FILING DATE: OCTOBER 24, 2003
 TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
 TRANSMEMBRANE AGONISTS
 INVENTOR(S): CARSON LOOMIS, ET AL.
 APPLICATION SERIAL NO.: UNASSIGNED



APPLICATION FILING DATE: OCTOBER 24, 2003
 TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
 TRANSMEMBRANE AGONISTS
 INVENTOR(S): CARSON LOOMIS, ET AL.
 APPLICATION SERIAL NO.: UNASSIGNED






Fig 6-S

Fig 6-T


APPLICATION FILING DATE: OCTOBER 24, 2003
 TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
 TRANSMEMBRANE AGONISTS
 INVENTOR(S): CARSON LOOMIS, ET AL.
 APPLICATION SERIAL NO.: UNASSIGNED




APPLICATION FILING DATE: OCTOBER 24, 2003
 TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
 TRANSMEMBRANE AGONISTS
 INVENTOR(S): CARSON LOOMIS, ET AL.
 APPLICATION SERIAL NO.: UNASSIGNED




APPLICATION FILING DATE: OCTOBER 24, 2003
 TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
 TRANSMEMBRANE AGONISTS
 INVENTOR(S): CARSON LOOMIS, ET AL.
 APPLICATION SERIAL NO.: UNASSIGNED




APPLICATION FILING DATE: OCTOBER 24, 2003
 TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
 TRANSMEMBRANE AGONISTS
 INVENTOR(S): CARSON LOOMIS, ET AL.
 APPLICATION SERIAL NO.: UNASSIGNED




APPLICATION FILING DATE: OCTOBER 24, 2003
 TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
 TRANSMEMBRANE AGONISTS
 INVENTOR(S): CARSON LOOMIS, ET AL.
 APPLICATION SERIAL NO.: UNASSIGNED



APPLICATION FILING DATE: OCTOBER 24, 2003
 TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
 TRANSMEMBRANE AGONISTS
 INVENTOR(S): CARSON LOOMIS, ET AL.
 APPLICATION SERIAL NO.: UNASSIGNED



APPLICATION FILING DATE: OCTOBER 24, 2003
 TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
 TRANSMEMBRANE AGONISTS
 INVENTOR(S): CARSON LOOMIS, ET AL.
 APPLICATION SERIAL NO.: UNASSIGNED




APPLICATION FILING DATE: OCTOBER 24, 2003

TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION


TRANSMEMBRANE AGONISTS

INVENTOR(S): CARSON LOOMIS, ET AL.

APPLICATION SERIAL NO.: UNASSIGNED



APPLICATION FILING DATE: OCTOBER 24, 2003
 TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
 TRANSMEMBRANE AGONISTS
 INVENTOR(S): CARSON LOOMIS, ET AL.
 APPLICATION SERIAL NO.: UNASSIGNED



APPLICATION FILING DATE: OCTOBER 24, 2003
 TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
 TRANSMEMBRANE AGONISTS
 INVENTOR(S): CARSON LOOMIS, ET AL.
 APPLICATION SERIAL NO.: UNASSIGNED






Fig 7-O


Fig 7-P

APPLICATION FILING DATE: OCTOBER 24, 2003
 TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
 TRANSMEMBRANE AGONISTS
 INVENTOR(S): CARSON LOOMIS, ET AL.
 APPLICATION SERIAL NO.: UNASSIGNED






APPLICATION FILING DATE: OCTOBER 24, 2003
 TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
 TRANSMEMBRANE AGONISTS
 INVENTOR(S): CARSON LOOMIS, ET AL.
 APPLICATION SERIAL NO.: UNASSIGNED



APPLICATION FILING DATE: OCTOBER 24, 2003
 TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
 TRANSMEMBRANE AGONISTS
 INVENTOR(S): CARSON LOOMIS, ET AL.
 APPLICATION SERIAL NO.: UNASSIGNED



APPLICATION FILING DATE: OCTOBER 24, 2003
 TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
 TRANSMEMBRANE AGONISTS
 INVENTOR(S): CARSON LOOMIS, ET AL.
 APPLICATION SERIAL NO.: UNASSIGNED




Fig 8-A

Fig 8-B

APPLICATION FILING DATE: OCTOBER 24, 2003
 TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
 TRANSMEMBRANE AGONISTS
 INVENTOR(S): CARSON LOOMIS, ET AL.
 APPLICATION SERIAL NO.: UNASSIGNED




Fig 8-C

Fig 8-D

APPLICATION FILING DATE: OCTOBER 24, 2003
 TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
 TRANSMEMBRANE AGONISTS
 INVENTOR(S): CARSON LOOMIS, ET AL.
 APPLICATION SERIAL NO.: UNASSIGNED